Lopinavir/ritonavir sprinkle formulation - Cipla

Drug Profile

Lopinavir/ritonavir sprinkle formulation - Cipla

Alternative Names: Lopimune Sprinkles; Lopinavir/ritonavir mini-melt tablets formulation; Lopinavir/ritonavir oral pellets; Ritonavir/lopinavir

Latest Information Update: 07 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cipla
  • Developer Cipla; Drugs for Neglected Diseases Initiative Foundation
  • Class Amides; Antiretrovirals; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections
  • No development reported HIV infections

Most Recent Events

  • 01 Dec 2015 Phase-III clinical trials in HIV-1 infections (In children) in Kenya (PO)
  • 03 Jun 2015 Cipla collaborates with University College London for development of sprinkle formulation of lopinavir/ritonavir for HIV-1 infections before June 2015
  • 28 May 2015 Cipla has patent pending for Lopinavir and ritonavir sprinkles formulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top